Moderna and Merck say melanoma vaccine succeeded in large trial

A personalized mRNA cancer vaccine (intismeran), combined with Merck's Keytruda, slowed the return of melanoma and its spread to other parts of the body in a late-stage Phase 3 clinical trial, the first randomized trial of its kind to test a neoantigen vaccine's benefit in cancer treatment.

These are interim results from a trial that is still running, and the drugmakers have not released the detailed data. The companies say they aim to file for regulatory approval within months.